Rare Diseases in MENA: Opportunities and Challenges

Rare diseases are individually uncommon but collectively powerful drivers of unmet need, costs, and innovation. In the Middle East and North Africa (MENA), structural, demographic, and genetic features, including high consanguinity rates, founder effects, growing genomic initiatives, and expanding health-system investments, make the region both a hotspot for rare genetic conditions and an important arena for developing solutions that can deliver clinical and economic impact. This article examines the burden of rare disease in MENA, the region’s significant opportunities (genomics, newborn screening, gene and cell therapy hubs, public–private partnerships), the systemic obstacles (diagnostic odysseys, fragmented registries, reimbursement, workforce constraints), and pragmatic steps to accelerate patient access and research while protecting privacy and equity.

How Big is “rare” and Why Mena Matters

Globally, rare diseases are now a formal public health priority: the World Health Assembly in 2025 recognized them as a global health priority for equity and inclusion, underscoring the need for national strategies and better data.

Two practical points about scale and genetics: (1) while each condition affects small numbers, there are thousands of distinct rare diseases and, cumulatively, millions of patients; (2) the MENA region carries a disproportionate share of inherited rare disorders because of demographic and genetic factors (consanguinity, founder mutations and endogamy), which increase autosomal recessive disease prevalence and create distinct mutation spectra relevant for diagnostics and therapeutics. These facts mean that investments in diagnostics, registries, and tailored therapies can have an outsized regional impact.

Regional Burden and Policy Recognition

Several MENA nations have begun to treat rare diseases as system priorities rather than isolated clinical problems:

• Saudi Arabia: The Ministry of Health has clearly defined rare diseases and initiated policy work and awareness initiatives to establish national definitions and pathways. The Saudi MOH provides public-facing information on rare diseases and frames them as a public health issue that requires coordinated policy responses.
• United Arab Emirates (Abu Dhabi / Emirates Genome Programme): Abu Dhabi’s genomics initiatives, including the Emirates Genome Programme and related genomics/precision medicine frameworks, have generated very large population genomic datasets (hundreds of thousands of samples), positioning the UAE as a regional genomic research hub. These data are explicitly linked to the improved identification of hereditary diseases and precision care opportunities.
• Qatar (Sidra Medicine): Sidra Medicine has publicly announced the establishment of a Gene Therapy Centre and is actively publishing region-specific genetics research, while building capacity to treat pediatric genetic disorders.
• Bahrain and other states: Bahrain’s Ministry of Health lists a national genome program intended to identify common mutations and support genomic medicine across the population. Similar national genomics strategy elements are emerging across Kuwait, Oman and Qatar.

These actions demonstrate rising political will across MENA to capture genomic data, improve diagnosis, and integrate rare disease care into national health strategies.

Why MENA Presents Opportunity for Rare-Disease Action

1. High yield for genomic sequencing and newborn screening — large, ethnically cohesive population pockets and the higher prevalence of specific inherited disorders make genomic sequencing and expanded newborn screening particularly effective at detecting actionable conditions early. Abu Dhabi’s Emirati Genome Programme (hundreds of thousands of genomes collected) is a clear example of the data-infrastructure scale that enables discovery and targeted screening.
2. Concentrated patient populations accelerate clinical research — founder mutations and family clusters can facilitate the identification of homogeneous patient cohorts, thereby shortening recruitment time for natural history studies and early-phase trials, provided ethical and regulatory frameworks are in place.
3. Growing advanced-therapy infrastructure — major tertiary centers (e.g., Sidra in Qatar) and specialty hospitals in the GCC are creating gene-therapy and cell-therapy capabilities, which can host regional clinical trials and later provide access programs.
4. Public–private willingness to invest — government entities and sovereign investors across the Gulf have prioritized life sciences capacity-building, attracting global pharma, diagnostics, and analytics players that already run rare-disease programs worldwide. Companies such as Novartis, Roche, and Pfizer publicly maintain robust rare-disease portfolios and patient access initiatives that can be adapted to local contexts.
5. Policy momentum — WHO recognition, coupled with national genome programs and regulatory modernization in multiple states, creates a policy environment where rare disease action plans, registries, and reimbursement pilots are feasible.

Key Structural Challenges for MENA Rare-Disease Ecosystems

Despite opportunities, systemic barriers slow progress. Below are the principal bottlenecks and their regional manifestations.

Diagnostic Odyssey and Limited Clinical Genetics Capacity

Patients often endure prolonged diagnostic journeys involving multiple specialists and delayed referrals to geneticists. A shortage of trained clinical geneticists, genetic counsellors, and specialized metabolic laboratories remains common across certain countries in the region, particularly outside major urban hubs. While tertiary centers (e.g., Sidra, King Faisal Specialist Hospital in Saudi Arabia) deliver advanced services, geographic and workforce gaps persist.

Evidence & implication: Building lab networks and training programs (medical genetics and counseling), supported by national genomics investments,  is a necessary near-term priority to convert sequencing capacity into timely patient diagnoses.

Fragmented Registries and Inconsistent Definitions

Many countries lack a unified, national rare-disease registry with standardized case definitions and interoperable data standards. Variable definitions (what counts as “rare”) complicate cross-border comparisons and pooled research. Saudi Arabia’s recent policy work to shape a national rare-disease definition highlights this challenge and the need for harmonization.

Access, Reimbursement, and High-Cost Therapies

Advanced therapies (gene therapy, cell therapy, enzyme replacement) are often one-time or ultra-expensive treatments. Absent risk-sharing agreements, outcomes-based contracting, and budget-impact planning, many national payers struggle to provide timely access. Planning for payment models that align high upfront costs with long-term benefits is a pressing policy request.

Ethics, Data Governance, and Public Trust

Large genomic projects raise legitimate privacy, consent, and governance questions. The Emirati Genome initiative’s scale drew both praise for its scientific potential and scrutiny about data custodianship and confidentiality. Transparent governance, robust de-identification, clear benefit-sharing policies, and public engagement are crucial for maintaining participation and international collaboration.

Uneven Clinical Trial Access

Clinical trials are still concentrated in a small number of academic centers, limiting patient exposure to experimental therapies. Expanding clinical trial capacity, regulatory clarity, ethics committees experienced with advanced therapy trials, and logistics for cold-chain products will be essential for equitable access.

Real Examples and Country Actions (What’s Already Happening)

• UAE / Abu Dhabi (Emirates Genome Programme): A national genomics effort has assembled extensive datasets (hundreds of thousands of genomes/samples), enabling population-specific variant discovery and supporting newborn and precision medicine initiatives. This program provides a backbone for variant interpretation that is directly relevant to rare disease diagnosis and sequencing-led screening.
• Saudi Arabia (Saudi Human Genome Program & MOH work): National projects such as the Saudi Human Genome Program and MOH initiatives have prioritized genetic disease research and policy efforts to define rare disease frameworks. These programs support localized reference datasets and clinical genetics capacity.
• Qatar (Sidra Medicine): Sidra’s Gene Therapy Centre and recent genomic research outputs demonstrate a clinical and translational pipeline for pediatric rare diseases, including participation in gene-therapy care models and newborn sequencing collaborations.
• Bahrain: Bahrain’s ministry lists a national genome program with explicit goals to identify common population mutations, an important step toward targeted carrier screening and newborn testing frameworks.
• Regional convenings: The MENA Congress for Rare Diseases and regional networks have become platforms for sharing clinical protocols, registries, and advocacy efforts, thereby strengthening cross-border collaboration.

Role of Industry and How Public–Private Collaboration Can Work

Global pharmaceutical and diagnostics companies are already engaged in rare disease research, drug development, diagnostics, and patient support programs. Examples of how the private sector can contribute:

• Diagnostics & lab networks (Roche and others): Companies provide diagnostics platforms and algorithms that shorten time to molecular diagnosis and enable decentralized testing.
• Gene and cell therapy developers (Novartis, Pfizer, and peers): Major developers have gene-therapy portfolios, access programs, and experience negotiating novel payment mechanisms (outcomes-based or annuity models), which can be adapted to national health systems.
• Clinical trial partnerships: Pharma can collaborate with national centers to run multi-site trials and to establish local manufacturing or fill-finish capacity for advanced therapies as part of access plans.

Key principle: public–private partnerships must be transparent, ethically governed, and designed to strengthen domestic capacity rather than creating dependence. Conditional technology transfer, local training, and equitable data-sharing terms should be central.

Practical, High-impact Recommendations for MENA Policymakers

1. Adopt a national rare-disease strategy with clear definitions and registry mandates. A consistent national definition and a secure, interoperable registry (with minimal mandatory dataset fields) enable planning, research and procurement forecasting. Saudi MOH and other national efforts provide useful templates.
2. Scale newborn screening and founder-mutation panels in tandem with counseling capacity. Where population-specific pathogenic variants are known, targeted screening panels can be high-value and cost-effective; broader sequencing approaches should be rolled out where infrastructure and counselling exist. Emirati and Bahraini genome programs illustrate the utility of population data to inform screening design.
3. Build a clinical genetics and counseling workforce through regional centers of excellence. Use “hub-and-spoke” models so tertiary centers (e.g., Sidra, KAIMRC/King Faisal) supply training and remote support to peripheral hospitals.
4. Modernize regulatory pathways for advanced therapies and adaptive reimbursement. Create fast-track, evidence-based pathways for ATMPs (advanced therapy medicinal products), and pilot outcome-based payment models for selected high-impact therapies to manage budget risk.
5. Ensure robust data governance and community engagement. Large genomic datasets are useful only if participants trust the systems. Transparent consent, clear governance on commercial use, and benefit-sharing commitments (e.g., reinvestment in local healthcare capacity) are essential.
6. Encourage local manufacturing/tech transfer where feasible. For biologics, fill-finish and cold-chain logistics, local capacity reduces supply-chain risk and can lower long-term costs.
7. Promote regional collaboration on registries, natural history studies, and pooled procurement. Shared registries and collaborative trials across MENA can yield critical mass for rare-disease knowledge and negotiating power for therapies.

Ethical & Equity Considerations

Clear ethical standards must accompany the acceleration of diagnostics and therapies:

• Equitable access across nationals and expatriates — national systems must articulate how high-cost therapies will be allocated fairly.
• Informed consent and re-contact policies — genomic projects must define re-contact policies for actionable incidental findings.
• Data sovereignty vs. collaboration — countries must balance the benefits of international research partnerships with protections for participant data and fair benefit sharing.

What Success Looks Like by 2030

A realistic, high-value target mix for MENA by 2030:

• National rare-disease registries in every GCC country with agreed minimal datasets and cross-border interoperability protocols.
• Expanded newborn screening informed by population variant panels in high-prevalence areas.
• At least 3–5 regional centers of excellence offering gene and cell therapy with ethical, regulatory, and reimbursement frameworks in place to deliver selected high-impact ACETs (advanced cell and gene therapies).
• Outcome-based reimbursement pilots for at least two ultra-expensive therapies, with data-driven assessment of long-term value.
• A regional network of trained genetic counselors and at least one regional reference laboratory for rare metabolic and genetic testing.

The Policy Window is Open

The MENA region stands at an inflection point: characterized by a high prevalence of inherited rare diseases, ambitious national genomics programs, leading hospitals building gene-therapy capacity, and active interest from global pharmaceutical companies, creating a unique opportunity. Converting promises into sustained patient impact will require system-level investments, including registries, workforce development, transparent data governance, financing innovation for high-cost therapies, and pragmatic public–private partnerships.

Policymakers should adopt coordinated plans for rare diseases that strike a balance between scientific ambition and ethical safeguards, as well as ensuring equitable access. For the private sector and academic partners, the region offers scientifically valuable cohorts and a chance to pilot sustainable access models that could set global precedents. With deliberate policy design and cross-sector collaboration, MENA can transform rare disease care from a niche challenge into a regional strength, delivering measurable improvements for patients and families who have waited too long for answers and effective treatments.